Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lymphocyte-specific protein 1 short hairpin RNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Lymphocyte-specific protein 1 short hairpin RNA (LSP1-shRNA) is an experimental gene-silencing agent designed to reduce the expression of the *LSP1* gene via RNA interference (RNAi). LSP1 is an intracellular F-actin binding protein primarily expressed in leukocytes and endothelial cells, where it regulates actin cytoskeleton remodeling and cell migration. In the context of oncology, particularly hepatocellular carcinoma (HCC), LSP1 has been identified as a potential promoter of tumor cell proliferation, migration, and invasion. By utilizing a short hairpin RNA structure, typically delivered via a viral vector such as lentivirus, this agent triggers the RNA-induced silencing complex (RISC) to degrade LSP1 mRNA. This knockdown aims to inhibit oncogenic signaling pathways and reduce the metastatic potential of tumor cells, making it a valuable tool for studying the functional role of LSP1 in cancer progression and inflammatory responses.
- Other names
- LSP1-shRNALSP-1-shRNALSP 1-shRNAshRNA-LSP1shRNA-LSP-1shRNA-LSP 1shRNA targeting LSP1
Beyond the preview
Go deeper on lymphocyte-specific protein 1 short hairpin RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lymphocyte-specific protein 1 short hairpin RNA.